The foundation said the money will also support making generic versions of Merck’s drug.
“To end this pandemic, we need to ensure that everyone, no matter where they live in the world, has access to lifesaving health products. The unjust reality, however, is that low-income countries have had to wait for everything from personal protective equipment to vaccines. That is unacceptable,” Melinda French Gates, co-chair of the foundation, said in a news release.
Merck applied for emergency use authorization for molnupiravir Oct. 11 and has released data showing that the pill reduced the risk of hospitalization or death from COVID-19 by about 50 percent in a phase 3 trial. The drugmaker asked for the drug to be authorized to treat mild to moderate COVID-19 in adults at risk of progressing to severe disease.
The Bill & Melinda Gates Foundation said it is hoping to reduce the time it takes for new drugs to reach low-income countries after their approval, and said the standard gap in rolling out global health products can be 12 months or more.
Read the full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
